Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757785 | 1.00 | PABPC1 (0.38) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL15756122 | 1.00 | PABPC1 (0.38) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL19714170 | 1.00 | PABPC1 (0.38) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL19714171 | 1.00 | PABPC1 (0.38) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL2757775 | 0.92 | PABPC1 (0.36) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL16807931 | 0.88 | PABPC1 (0.38) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL2757796 | 0.86 | PABPC1 (0.39) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL1487324 | 0.84 | PABPC1 (0.39) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL8637706 | 0.84 | PABPC1 (0.39) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL17801227 | 0.84 | PABPC1 (0.39) | PABPC1CTDSP1GAATMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271344-B1 | PROCESS FOR PREPARING AMINOTETRAHYDROPYRANS | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2020-08-26 | — | — | EP | disclosed |
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| US-10377732-B2 | Process for preparing aminotetrahydropyrans | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-08-13 | — | — | US | disclosed |
| US-20180290995-A1 | Process For Preparing Aminotetrahydropyrans | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-10-11 | — | — | US | disclosed |
| US-10072011-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2018-09-11 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| WO-2016079710-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377732-B2 | Process for preparing aminotetrahydropyrans | DPP4, DPP3, DPP9 | PABPC1 1347/4885CTDSP1 2812/4885GAA 792/4885 |
| US-10072011-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | PABPC1 4010/4885CTDSP1 2345/4885GAA 1087/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PABPC1 4010/4885CTDSP1 2345/4885GAA 1087/4885 |
| US-20180290995-A1 | Process For Preparing Aminotetrahydropyrans | DPP4, DPP3, DPP9 | PABPC1 1347/4885CTDSP1 2812/4885GAA 792/4885 |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | LPAR4, LPAR2, LPAR5 | PABPC1 1772/4885CTDSP1 2724/4885GAA 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.